The global retinal biologics market was valued at USD 10,732.7 million in 2019. Increase in prevalence of retinal disorders such as diabetic retinopathy, macular degeneration, rapidly growing geriatric patient pool and increasing focus on R&D activities to develop advanced products are key factors driving the global retinal biologics market.
Retinal biologics are biologically derived molecules used for the treatment of retinal disorders. Avastin, Lucentis, and Eylea are some of the widely used retinal biologics in the market. Increase in the prevalence of retinal disorders such as age-related macular degeneration, retinal vein occlusions, and diabetic retinopathy across the globe are major factors driving the global retinal biologics market. According to the National Eye Institute (NEI), approximately 2.0 million people in the U.S. were affected with age-related macular degeneration (AMD) in 2010, and the number is expected to more than double to reach an estimated 5.4 million by 2050. Moreover, rapidly growing elderly patient pool is at high risk of developing retinal disorders such as macular degeneration. This, in turn, will lead to rise in demand for retinal biologics in the next few years.
The global retinal biologics market has been segmented based on drug class, application, and region. On the basis of drug class, the global retinal biologics market is categorized into VEGF antagonists, and TNF-a inhibitors. VEGF antagonists segment held the largest share of global market in 2019 owing to increased therapeutic benefits offered for the treatment of patients with retinal disorders. Application-wise, the global retinal biologics market is segmented into diabetic retinopathy, uveitis, age-related macular degeneration and others. Age-related macular degeneration segment dominated the global retinal biologics market in 2019. Geographically, North America dominated the global retinal biologics market in 2019, however, Asia Pacific is expected to be the fastest growing region by 2028.
Key players operating in the global retinal biologics market include F. Hoffmann-La Roche, Regeneron Pharmaceuticals Inc., AbbVie Inc., MeiraGTx Limited, Oxurion NV, Novartis, Merck & Co., Inc., Allergan, and Santel Pharmaceuticals among others.
Retinal Biologics Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||USD 18.3 billion|
|Growth Rate||CAGR of 6.5% during 2021-2028|
|Segment Covered||Drug Class, Indication, Application, Regions|
|Regions Covered||North America, Europe, Asia Pacific, Middle East and Africa, Latin America|
|Key Players Profiled||F. Hoffmann-La Roche, Regeneron Pharmaceuticals Inc., AbbVie Inc., MeiraGTx Limited, Oxurion NV, Novartis, Merck & Co., Inc., Allergan, and Santel Pharmaceuticals among others.|
Key Segments of the Global Retinal Biologics Market
Drug Class Overview, 2018-2028 (USD Million)
- VEGF Antagonists
- TNF-a Inhibitors
Application Overview, 2018-2028 (USD Million)
- Diabetic Retinopathy
- Macular Degeneration
Regional Overview, 2018-2028 (USD Million)
- North America
- United Kingdom
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa
Reasons for the study
- Increase in prevalence of retinal disorders
- Rapid technology advancements
- Increase in geriatric population across the globe
What does the report include?
- The study on the global retinal biologics market includes qualitative insights such as drivers, restraints, challenges and opportunities
- Additionally, the market has been evaluated using the Porter’s Five Forces analysis
- The study covers qualitative and quantitative analysis of the market segmented on the basis of drug class, application, and region.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments
- The study includes the profiles of key players operating in the market
Who should buy this report?
- The report on the global retinal biologics market is suitable for all the players across the value chain including raw material suppliers, hospitals & clinics, medical device manufacturers, healthcare organizations, ophthalmologists, distributors, suppliers and technology geeks
- Venture capitalists and investors looking for more information on the future outlook of the global retinal biologics market
- Consultants, analysts, researchers, and academicians looking for insights shaping the global retinal biologics market
Disorders of the blood vessels in the retina are some of the major causes of blindness among children and adults across the globe. These disorders include diabetic retinopathy, age-related macular degeneration, and retinopathy of prematurity. These disorders are caused by over-production of a protein called vascular endothelial growth factor. Thus, wide range of retinal biologics which act as a VEGF antagonists are available in the market, including Eylea, Lucentis and Avastin. Surging elderly patient pool suffering from age-related ophthalmic disorders is further expected to drive the global retinal biologics market. Moreover, major industry players are also investing in R&D in order to develop technologically advanced products for the treatment of retinal disorders which is expected to accelerate the growth of the market in the future. For instance, in July 2019, Novartis AG received a positive CHMP opinion for Lucentis, for infants suffering from retinopathy of prematurity.
The global retinal biologics market has been segmented based on drug class, indication, and region. Based on drug class, the global retinal biologics market is categorized into VEGF-antagonists and TNF-a inhibitors. Vascular endothelial growth factor (VEGF) antagonists segment held substantial share of the global market in 2019. Increase in prevalence of age-related macular degeneration and presence of well-established players offering VEGF antagonists such as Lucentis (ranibizumab), Macugen (pegaptanib), and Avastin (bevacizumab) will drive segment growth. TNF-a inhibitors segment is anticipated to grow at a rapid pace over the coming years. TNF-a inhibitors are widely used in ophthalmology that increases corneal wound healing and repairs retinal damage. These biologics are extensively used in ophthalmology as an alternative to conventional immunosuppressive treatments for non-infectious uveitis.
Application-wise, the global retinal biologics market is segregated into diabetic retinopathy, age-related macular degeneration, uveitis and others. Age-related macular degeneration (AMD) segment accounted for majority of the market share in 2019. Diabetic retinopathy will witness lucrative growth over the coming years owing to rapidly growing population suffering from diabetes and diabetic retinopathy which is expected to drive the demand for retinal biologics in the future.
The global retinal biologics market is cumulative to North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America dominated the global retinal biologics market in 2019, however Asia Pacific is expected to grow at a rapid pace through 2028.
Higher adoption of retinal biologics along with presence of large diabetic population in the U.S. and Canada is a major factor expected to drive the retinal biologics market in the region. According to CDC, approximately 100 million people in the U.S. and around 3.6 million people in Canada are suffering from diabetes, which increases the risk of developing diabetic retinopathy. Furthermore, presence of large elderly patient population, coupled with launch of technologically advanced products by key industry players are other major factors likely to boost the growth of the market in North America.
However, Asia Pacific is expected to grow at a rapid pace over the next few years. There is a strong growth potential in the emerging economies such as India, and China. The rapidly rising geriatric population in countries such as India and China provide large market for retinal biologics. Increase in prevalence of retinal diseases, presence of large diabetic population in Japan, China and India will further boost the growth of the market in the coming years.